Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC3178
Trial ID NCT05537766
Disease Waldenstrom Macroglobulinemia | Burkitt Lymphoma | Hairy Cell Leukemia
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment KTE-X19|Tecartus|Brexucabtagene autoleucel
Location approved US, EU, UK, Australia, Canada
Generation2nd
PhasePhase2
Recruitment statusRecruiting
TitleStudy of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
Year2022
CountryUnited States
Company sponsorKite, A Gilead Company
Other ID(s)KT-US-568-0138|2022-501259-10-00|2022-501260-18-00|2022-501261-46-00|2022-501262-21-00
Vector information
Vectorlentivirus
ConstructscFv-CD28-CD3ζ

Clinical Result

Cohort1: Waldenstrom Macroglobulinemia
Administration route intravenous infusion
Dosage 2E6 cells/kg, single infusion
Donor type Autologous
Age Adult, Older_Adult
Lymph depletion Yes
Cohort2: Richter Transformation
Administration route intravenous infusion
Dosage 2E6 cells/kg, single infusion
Donor type Autologous
Age Adult, Older_Adult
Lymph depletion Yes
Cohort3: Burkitt Lymphoma
Administration route intravenous infusion
Dosage 2E6 cells/kg, single infusion
Donor type Autologous
Age Adult, Older_Adult
Lymph depletion Yes
Cohort4: Hairy Cell Leukemia
Administration route intravenous infusion
Dosage 2E6 cells/kg, single infusion
Donor type Autologous
Age Adult, Older_Adult
Lymph depletion Yes

Relationship Graph

Overview of Knowledge Graph